- Home
- MPV vs NGEN Comparison
MPV vs NGEN Comparison
Compare MPV & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MPV | NGEN |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 197.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MPV | NGEN |
|---|---|---|
| Price | $15.85 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 11.5K | ★ 833.4K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.65 | $1.59 |
| 52 Week High | $21.00 | $5.93 |
Technical Indicators
Market Signals| Indicator | MPV | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 35.28 |
| Support Level | $15.65 | $1.70 |
| Resistance Level | $17.57 | $2.28 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 12.70 | 19.84 |
Price Performance
Historical ComparisonAbout MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.